相似文献
1
Correlation of anti-tumour drug resistance with epigenetic regulation.
Br J Cancer. 2021 Feb;124(4):681-682. doi: 10.1038/s41416-020-01183-y. Epub 2020 Dec 3.
2
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.
Eur J Pharmacol. 2022 Jul 15;927:175071. doi: 10.1016/j.ejphar.2022.175071. Epub 2022 May 27.
3
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
Ann Med. 2015;47(5):359-69. doi: 10.3109/07853890.2015.1043140. Epub 2015 Jul 10.
4
Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Clin Breast Cancer. 2018 Jun;18(3):189-191. doi: 10.1016/j.clbc.2017.09.009. Epub 2017 Sep 19.
5
Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators.
Curr Cancer Drug Targets. 2021;21(4):353-359. doi: 10.2174/1568009620666210108102723.
6
Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities.
Curr Drug Metab. 2019;20(14):1114-1131. doi: 10.2174/1389200221666200103111539.
7
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.
Oncogene. 2013 Sep 19;32(38):4586-92. doi: 10.1038/onc.2012.477. Epub 2012 Nov 5.
8
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Br J Cancer. 2008 May 6;98(9):1515-24. doi: 10.1038/sj.bjc.6604334. Epub 2008 Apr 1.
9
Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
Anticancer Res. 2016 Jan;36(1):1-4.
10
DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through Overexpression in Cancer Cells.
Theranostics. 2017 Sep 22;7(17):4118-4134. doi: 10.7150/thno.20112. eCollection 2017.
引用本文的文献
1
Reflections and perspectives on epigenetically mediated biological control: compromises in cancer and skeletal pathology.
Acad Biol. 2025;3(2). doi: 10.20935/AcadBiol7628. Epub 2025 Apr 11.
2
Recent progress of iron-based nanomaterials in gene delivery and tumor gene therapy.
J Nanobiotechnology. 2024 Jun 2;22(1):309. doi: 10.1186/s12951-024-02550-0.
3
Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers.
Medicina (Kaunas). 2023 Sep 27;59(10):1722. doi: 10.3390/medicina59101722.
4
Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role.
Med Oncol. 2023 Aug 7;40(9):264. doi: 10.1007/s12032-023-02138-y.
5
Mass Spectrometry Contribution to Pediatric Cancers Research.
Medicina (Kaunas). 2023 Mar 20;59(3):612. doi: 10.3390/medicina59030612.
6
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy.
Pharmaceutics. 2023 Jan 21;15(2):364. doi: 10.3390/pharmaceutics15020364.
7
Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth.
iScience. 2022 Jul 15;25(8):104752. doi: 10.1016/j.isci.2022.104752. eCollection 2022 Aug 19.
8
Epigenetic regulation and targeting of ECM for cancer therapy.
Am J Physiol Cell Physiol. 2022 Apr 1;322(4):C762-C768. doi: 10.1152/ajpcell.00022.2022. Epub 2022 Mar 2.
9
The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis.
Cancers (Basel). 2021 Nov 3;13(21):5516. doi: 10.3390/cancers13215516.
Zotero 插件